Pharma — December 2023
-
Valuta
EURUSD | +0,2% | 1,0906 dollar
USDJPY | -0,1% | 148,08 yen
EURJPY | +0,1% | 161,53 yen
GBPUSD | +0,1% | 1,2640 dollar -
Kilde: Nordnet
-
Astellas' Veoza Approved In Europe For Treatment Of Vasomotor Symptoms Associated With Menopause https://www.proinvestor.com/investornyt/1088746/astellas-veoza-approved-in-europe-for-treatment-of-vasomotor-symptoms-associated-with-menopause
-
Novartis : Phase III Trial Results Show Sustained Efficacy & Long-term Safety Of Fabhalta In PNH https://www.proinvestor.com/investornyt/1088751/novartis-phase-iii-trial-results-show-sustained-efficacy-amp-long-term-safety-of-fabhalta-in-pnh
-
AstraZeneca : Phase III Trial Data Show Danicopan Sustained Clinical Improvements In PNH https://www.proinvestor.com/investornyt/1088753/astrazeneca-phase-iii-trial-data-show-danicopan-sustained-clinical-improvements-in-pnh
-
Danske Bank ser opkøb som mulig bro over truende patentkløft for Lundbeck https://www.proinvestor.com/investornyt/1088791/danske-bank-ser-opkob-som-mulig-bro-over-truende-patentkloft-for-lundbeck
-
Sanofi Terminates Pompe Disease Drug Agreement With Maze Therapeutics Following FTC Opposition https://www.proinvestor.com/investornyt/1089315/sanofi-terminates-pompe-disease-drug-agreement-with-maze-therapeutics-following-ftc-opposition
-
Pfizer Receives All Required Regulatory Approvals to Complete the Acquisition of Seagen https://www.pfizer.com/news/press-release/press-release-detail/pfizer-receives-all-required-regulatory-approvals-complete
-
Pfizer har øretæver i sigte efter skuffende prognose for næste år https://www.proinvestor.com/investornyt/1089999/pfizer-har-oretaever-i-sigte-efter-skuffende-prognose-for-naeste-ar
-
AbbVie (ABBV) Declines More Than Market: Some Information for Investors https://www.proinvestor.com/investornyt/1091670/abbvie-abbv-declines-more-than-market-some-information-for-investors
-
Eli Lilly (LLY) Dips More Than Broader Market: What You Should Know https://www.proinvestor.com/investornyt/1091668/eli-lilly-lly-dips-more-than-broader-market-what-you-should-know
-
ALK får lavere kursmål hos Kempen
22.12.2023 17.12 • MarketWire •
ALK-Abelló har fået reduceret kursmålet for aktien til 150 kr. fra 200 kr. hos Kempen.Anbefalingen er uændret "køb".
Det fremgår af Bloomberg.
Aktien faldt fredag 0,3 pct. til 99 kr.
.\˙ MarketWire
-
AstraZeneca To Buy Gracell For Up To $1.2 Bln https://www.proinvestor.com/investornyt/1095718/astrazeneca-to-buy-gracell-for-up-to-12-bln
-
Bristol Myers Squibb To Acquire RayzeBio For $62.50/share In All-cash Deal https://www.proinvestor.com/investornyt/1095756/bristol-myers-squibb-to-acquire-rayzebio-for-6250-share-in-all-cash-deal
-
Astrazeneca klar til at foretage et af de første opkøb i Kina https://www.proinvestor.com/investornyt/1096052/astrazeneca-klar-til-at-foretage-et-af-de-forste-opkob-i-kina
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind